|
|
Volumn 43, Issue SUPPL. 2, 2004, Pages
|
|
Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IXG250/MN
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBONATE DEHYDRATASE IX;
INTERLEUKIN 2;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY G250;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ANTIGEN ANTIBODY REACTION;
ANTIGEN PRESENTATION;
ANTIGEN RECOGNITION;
ANTINEOPLASTIC ACTIVITY;
CANCER IMMUNOTHERAPY;
CANCER INHIBITION;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONFERENCE PAPER;
CYTOTOXICITY;
DRUG EFFICACY;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG TARGETING;
HUMAN;
KIDNEY CARCINOMA;
KIDNEY METASTASIS;
MAXIMUM TOLERATED DOSE;
NATURAL KILLER CELL;
PROTEIN EXPRESSION;
SIDE EFFECT;
ANTIBODIES, MONOCLONAL;
ANTIBODY SPECIFICITY;
ANTIGENS, NEOPLASM;
CARBONIC ANHYDRASES;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS AS TOPIC;
CYTOTOXICITY TESTS, IMMUNOLOGIC;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG DELIVERY SYSTEMS;
DRUG THERAPY, COMBINATION;
HUMANS;
INTERLEUKIN-2;
KIDNEY NEOPLASMS;
NEOPLASM METASTASIS;
|
|
EID: 4744375262
PISSN: 03402592
EISSN: None
Source Type: Journal
DOI: 10.1007/s00120-004-0609-3 Document Type: Conference Paper |
|
Times cited : (11)
|
|
References (4)
|
